Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users
Completed · Phase 4 · NCT04995029
Conditions: Moderate to Severe Opioid-use Disorder
At a glance
- Research payments reported, 2025
- $201,905
- U.S. investigators named
- 6
- Sites paid
- 10
- Planned or actual enrollment
- 785
About the trial
- Sponsor
- Indivior Inc.
- Tested
- Transmucosal Buprenorphine (drug), Extended-release Buprenorphine (drug)
- Dates
- Started 2021-10-26; completion 2024-06-26
- Results posted
- Yes
The primary objective of the induction phase of the study is to compare treatment retention of participants following rapid induction or standard of care (SoC) induction onto extended-release buprenorphine. The primary objective of the maintenance phase is to compare the efficacy of 100 mg and 300 mg maintenance doses of extended-release buprenorphine administered every 4 weeks.
From ClinicalTrials.gov, last updated 2026-02-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Indivior Inc. reported $201,905 in research payments for this study in 2025 (586 payments).
Products named: Sublocade
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Eric M. Chavez, MD Psychiatry · San Diego, CA
- Rasheed A. Onafuye, M.D Psychiatry · Monroe, NC
- Alain H. Litwin, MD, MPH Addiction Medicine · Bronx, NY
- Gita -. Pujari II, M.D. Addiction Medicine · Oklahoma City, OK
- David M. Weitzman, M.D. Emergency Medicine · North Myrtle Beach, SC
- Michael S. Roundy, PHYSICIAN SURGEON Psychiatry · Bountiful, UT
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Pharmaseek LLC $41,785
- Artemis Headlands LLC $29,677
- Prisma Health PAtewood Hospital, SC $25,649
- Prisma Health Greenville Memorial Hospital, SC $25,649
- Llm Research $22,087
- Artemis Institute for Clinical Research $16,177
- Monroe Biomedical Research $15,584
- Pahl Pharmaceutical Proffessionals LLC $10,591
- Pahl Pharmaceutical Professionals LLC $10,591
- Alpine Research Organization Inc $4,114
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.